<DOC>
	<DOCNO>NCT00943995</DOCNO>
	<brief_summary>Hypotheses : 1 . The provision thrice weekly subcutaneous ( SQ ) recombinant growth hormone ( rGH ) therapy child receive in-center hemodialysis ( HD ) result improved growth . 2 . The provision thrice weekly SQ rGH therapy child receive in-center HD result improve lean body mass , nutritional status quality life . TIW rGH treatment regimen ( 0.35 mg/kg/week divide 3 dos , dose give conclusion dialysis treatment ) 2 year ; growth response , Dual energy X-ray absorptiometry ( DEXA ) , quality life ( QOL ) measure . The goal enroll 20 child Tanner 1 decrease height SDS and/or decrease height velocity standard deviation scoreS ( SDS ) . If therapy demonstrate efficacious improves growth QOL , therapy could easily implement eligible child HD , since parental acceptance well without administer rGH home compliance child assure . The investigator thus propose important study ability advance understand provide evidence best method promote growth child dialysis . The result study result important information value entire pediatric nephrologist community , include health care professional , patient , family . In real sense , study build 2006 Consensus Conference guideline evaluation treatment growth failure child chronic kidney disease ( CKD ) . This provide evidence critical management decision help insure good growth opportunity child CKD .</brief_summary>
	<brief_title>Three Times Weekly ( TIW ) Growth Hormone Therapy Children Hemodialysis</brief_title>
	<detailed_description>Objectives/Aims : 1 . To demonstrate beneficial effect thrice weekly SQ rGH Rx growth child HD 2 . To demonstrate beneficial effect thrice weekly SQ rGH Rx term improve lean body mass , nutritional status quality life child HD Study Design : 1 . Study group - Provision standard weekly dose SQ rGH ( 0.35 mg/kg/week divide 3 dos , dose give conclusion dialysis therapy ) 2 year growth retard ( Height SDS &lt; -1.88 Height velocity &lt; -1.88 SD ) child receive HD na√Øve rGH rGH least 12 month . Inclusion criterion : medically clear SQ rGH Rx ( 14 ) ; growth potential base Tanner stage 1 open epiphysis Bone Age radiograph ( Bone age &lt; 12 year ) ; expect require HD least 6 month ; least 6 month standardize historical pre-study anthropometric data ( include stadiometer height ) . Exclusion criterion include medical factor indicate rGH therapy use ( 14 ) , e.g. , poor nutritional status , poorly control acidosis , poor dialysis adequacy ( define Kt/V &lt; 1.2 ) , poorly control renal osteodystrophy ( PTH &gt; 800 ) . Once complicate factor address correct , child may consider study . 2 . SQ rGH provide in-center conclusion dialysis session three time weekly 24 month . SQ rGH dose adjust base dry ( euvolemic ) weight every month intervention . 3 . Baseline monitoring data obtain patient SQ rGH Rx . This include stadiometer measure height least 6 month prior initiation SQ rGH Rx provide important baseline height growth velocity use determine magnitude response . 4 . For child suboptimal response 6 month standard SQ rGH Rx dose ( annualized growth rate &lt; 2 cm precede year ) , rGH dose increase 0.70 mg/kg/week divide 3 dos ( similar report `` pubertal '' dose regimen use GH deficient child ) . Baseline data : Height ( stadiometer ) , Weight , BMI , Height SDS , Height velocity SDS ( historical past 6 month ) , Weight SDS , BMI SDS , Hb , BUN , nPCR , serum albumin , serum calcium , serum phosphorus , iPTH , electrolytes , high sensitivity CRP ( marker inflammation ) , dialysis adequacy ( define single double pool Kt/V - Kt/V unitless number use quantify hemodialysis peritoneal dialysis treatment adequacy : K - dialyzer clearance urea , - dialysis time , V - patient 's total body water ; HD target 1.2 ) , IGF-1 , IGFBP-3 , hip film bone age ( 4,5,6,9 ) . In addition , lean body mass/and fat mass assess DEXA ( standardize determination LBM , DEXA do mid week , dialysis treatment , avoid excess fluid commonly present 2 day dialysis weekend ) quality life assess PedsQL 4.0 Generic Core Scales ( 10 ) . The nutritional parameter determine ( wt/ht , ht SDS , BMI , nPCR serum albumin ) represent currently use assessment nutrition patient validate best measure nutrition child dialysis ( 12 ) . Assessments repeat follow interval : 1 . Height ( stadiometer ) , Weight , Hgb , BUN , nPCR , serum albumin , serum calcium , phosphorus , electrolytes , Kt/V - monthly 2 . CRP , iPTH , IGF-1 , IGFBP-3 - every 3 month 3 . PedsQL - every 6 month 4 . DEXA Bone Age - yearly ( within 1 week renal transplant occur anytime 6 month start study ) - DEXA Bone Age result send Nationwide Children 's analyzed collaborating pediatric radiologist ( Larry Binkovitz , MD ) .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Chronic Renal Failure Hemodialysis Tanner 1 Bone Age &lt; 12 Below 3rd % tile height growth velocity &lt; 3rd % tile SQ rGH Rx At baseline , study population also documentation normal thyroid status , secondary hyperparathyroidism control acceptable range ( iPTH &lt; 800 ) , adequate dialysis ( Kt/V &gt; 1.2 ) normal acidbase status . expect hemodialysis least 6 month Anyone meeting inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>End Stage Kidney Disease</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>Short stature</keyword>
	<keyword>Growth Hormone therapy</keyword>
</DOC>